Pediatric Relapsed Or Refractory B-Cell Acute Lymphoblastic Leukemia And B-Cell Non-Hodgkin Lymphoma
AUTLAutolus TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for AUCATZYL/Obecabtagene Autoleucel (AUTO1) (CD19 CAR-T) in Pediatric Relapsed Or Refractory B-Cell Acute Lymphoblastic Leukemia And B-Cell Non-Hodgkin Lymphoma. The expected timing is based on the latest available company guidance and may change.
08/11/26:- CATULUS Phase 2 pediatric B-ALL data remains expected by YE 2027.
Verification
Confirm timing and program details against the company announcement or filing.